El Bairi Khalid, Tariq Kanwal, Himri Imane, Jaafari Abdeslam, Smaili Wiam, Kandhro Abdul Hafeez, Gouri Adel, Ghazi Bouchra
Independent Research Team in Cancer Biology and Bioactive Compounds, Mohamed 1(st) University, Oujda, Morocco.
B-10 Jumani Center, Garden East, Karachi 74400, Pakistan.
Cancer Genet. 2018 Jan;220:49-76. doi: 10.1016/j.cancergen.2017.11.001. Epub 2017 Nov 15.
Colorectal cancer (CRC) is very heterogeneous and presents different types of epigenetic alterations including DNA methylation, histone modifications and microRNAs. These changes are considered as characteristics of various observed clinical phenotypes. Undoubtedly, the discovery of epigenetic pathways with novel epigenetic-related mechanisms constitutes a promising advance in cancer biomarker discovery. In this review, we provide an evidence-based discussing of the current understanding of CRC epigenomics and its role in initiation, epithelial-to-mesenchymal transition and metastasis. We also discuss the recent findings regarding the potential clinical perspectives of these alterations as potent biomarkers for CRC diagnosis, prognosis, and therapy in the era of liquid biopsy.
结直肠癌(CRC)具有高度异质性,呈现出不同类型的表观遗传改变,包括DNA甲基化、组蛋白修饰和微小RNA。这些变化被认为是各种观察到的临床表型的特征。毫无疑问,发现具有新型表观遗传相关机制的表观遗传途径是癌症生物标志物发现方面的一项有前景的进展。在本综述中,我们基于证据讨论了目前对CRC表观基因组学的理解及其在肿瘤发生、上皮-间质转化和转移中的作用。我们还讨论了这些改变作为液体活检时代CRC诊断、预后和治疗的有效生物标志物的潜在临床前景的最新发现。